Home » Newsletters » BioWorld Science

BioWorld Science

April 24, 2018

View Archived Issues

UCB to acquire Proximagen's midazolam nasal spray

EpimAb and Zhejiang Teruisi Biopharmaceutical enter development collaboration for FIT-012

GlaxoSmithKline describes novel TrpV4 antagonists

New phosphatidylinositol 3-kinase inhibitors identified at Gilead

Kalyra Pharmaceuticals presents novel ERK-1/2 inhibitors

BiopharmaTi divulges novel ketolide antibacterials

Roche discovers new gamma-secretase inhibitors

Sirolimus granted FDA orphan drug designation for the treatment of sickle cell disease

Sage submits NDA for intravenous brexanolone to treat postpartum depression

Prothena discontinues development of NEOD-001

Pfizer receives complete response letter from FDA for trastuzumab biosimilar

Voyager-V1 oncolytic virus under study in patients with solid tumors

FDA grants breakthrough therapy designation to Trumenba for children aged 1-9 years

CBT Pharmaceuticals and CrystalGenomics sign oncology codevelopment agreement

Autolus acquires rights to novel CD19 CAR T-cell therapy from UCL

E.U. approval for Mylotarg with chemotherapy for CD33-positive AML

FDA clears Ultragenyx's IND for phase I/II study of DTX-401 for glycogen storage disease type Ia

Novel PIM/PI3K inhibitor IBL-302 shows promise in preclinical cancer models

Astellas seeks Japanese and U.S. approval for gilteritinib in FLT3 mutation-positive AML

AOBiome Therapeutics initiates phase II study of ammonia oxidizing bacteria product candidate

Connect Biopharmaceuticals files to begin phase I study of CBP-201 in Australia

FDA advisory committee recommends baricitinib 2 mg, rejects 4-mg dose in rheumatoid arthritis

EMA validates type II variation for Keytruda with pemetrexed and chemotherapy in NSCLC

Q Therapeutics and Reprocell create joint venture

FDA issues partial clinical hold for tazemetostat trials

Researchers present potent EGFR T790M-mutant inhibitor E-191

AstraZeneca reports data from ARCTIC study of Imfinzi and tremelimumab in third-line NSCLC

Novel selective estrogen receptor degrader LX-039 selected for clinical development

Atozet launched in Japan

FDA grants fast track designation to AAV-RPGR

Malaria vaccine R-21 shows efficacy in a phase IIa trial

Celgene launches Istodax in Japan